CLC bio is taking part in a collaboration to develop a solution for the large-scale use of formalin fixed, paraffin embedded (FFPE) tissue in molecular analyses.
The project, which will be conducted with AROS Applied Biotechnology, F Hoffmann-La Roche and Aarhus University Hospital - the Institute of Pathology and the Research Unit for Molecular Medicine, aims to develop a complete platform for selecting appropriate FFPE samples, choosing the optimal sequencing technology, and subsequently assembling and analysing the high-throughput sequencing data.
The main application areas will be molecular diagnostics research and re-analysis of pre-clinical trials where drugs have failed despite relatively high rates of positive responses.
Using the proposed platform, researchers will have access to a wider range of samples than can be collected in traditional fresh tissue biobanks.
These samples can be efficiently linked to high-quality patient data through numerous healthcare, disease and population registries, providing opportunities to boost research in disease mechanisms and rescue drugs from failure.
